These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27029427)

  • 1. Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
    Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Hisamichi M; Hirata K; Kimura K; Shibagaki Y
    Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1366-76. PubMed ID: 27029427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1
    Ohata K; Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Katayama K; Asano J; Kimura K; Shibagaki Y
    Eur J Pharmacol; 2017 Nov; 815():88-97. PubMed ID: 28888756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
    Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
    Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
    Terawaki H; Hoshi H; Kazama JJ
    Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
    [No Abstract]   [Full Text] [Related]  

  • 5. Topiroxostat improves glomerulosclerosis in type 2 diabetic Nagoya Shibata Yasuda mice with early diabetic kidney disease.
    Hagiwara M; Ishiyama S; Nakamura T; Mochizuki K
    Eur J Pharmacol; 2024 Nov; 982():176915. PubMed ID: 39154822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.
    Tanaka T; Doi K; Maeda-Mamiya R; Negishi K; Portilla D; Sugaya T; Fujita T; Noiri E
    Am J Pathol; 2009 Apr; 174(4):1203-11. PubMed ID: 19264908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
    Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
    Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice.
    Nakamura T; Nampei M; Murase T; Satoh E; Akari S; Katoh N; Mizukami H
    Nutr Diabetes; 2021 Apr; 11(1):12. PubMed ID: 33850106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
    Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
    Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
    Sezai A; Obata K; Abe K; Kanno S; Sekino H
    Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.
    Tanaka T; Noiri E; Yamamoto T; Sugaya T; Negishi K; Maeda R; Nakamura K; Portilla D; Goto M; Fujita T
    Nephron Exp Nephrol; 2008; 108(1):e19-26. PubMed ID: 18182783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Shibagaki Y; Yasuda T; Hoshino S; Katayama K; Igarashi-Migitaka J; Hirata K; Kimura K
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F114-21. PubMed ID: 25339700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xanthine Oxidoreductase Inhibitors Suppress the Onset of Exercise-Induced AKI in High HPRT Activity
    Hosoya T; Uchida S; Shibata S; Tomioka NH; Matsumoto K; Hosoyamada M
    J Am Soc Nephrol; 2022 Feb; 33(2):326-341. PubMed ID: 34799437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Shibagaki Y; Yasuda T; Katayama K; Hoshino S; Igarashi-Migitaka J; Hirata K; Kimura K
    Am J Physiol Renal Physiol; 2014 Mar; 306(6):F655-63. PubMed ID: 24431207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
    Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
    Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice.
    Takahashi K; Mizukami H; Osonoi S; Ogasawara S; Hara Y; Kudoh K; Takeuchi Y; Sasaki T; Daimon M; Yagihashi S
    Neurobiol Dis; 2021 Jul; 155():105392. PubMed ID: 34000416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice.
    Kosaki K; Sugaya T; Ohata K; Tanabe J; Hoshino S; Inoue K; Kimura K; Maeda S; Shibagaki Y; Kamijo-Ikemori A
    Hypertens Res; 2019 Oct; 42(10):1518-1527. PubMed ID: 31168059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
    Fahmi AN; Shehatou GS; Shebl AM; Salem HA
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):819-30. PubMed ID: 27215580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors.
    Shimo T; Moto M; Ashizawa N; Matsumoto K; Iwanaga T; Saito K
    Arch Toxicol; 2014 Apr; 88(4):1035-42. PubMed ID: 24448833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis.
    Peleli M; Zollbrecht C; Montenegro MF; Hezel M; Zhong J; Persson EG; Holmdahl R; Weitzberg E; Lundberg JO; Carlström M
    Free Radic Biol Med; 2016 Oct; 99():472-484. PubMed ID: 27609225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.